MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.800
-0.090
-1.84%
Pre Market: 4.690 -0.11 -2.29% 04:59 09/28 EDT
OPEN
4.860
PREV CLOSE
4.890
HIGH
4.920
LOW
4.750
VOLUME
50
TURNOVER
--
52 WEEK HIGH
8.09
52 WEEK LOW
1.910
MARKET CAP
143.76M
P/E (TTM)
-11.7965
1D
5D
1M
3M
1Y
5Y
10 Best Biotech Stocks Under $10
In this article, we discuss the 10 best biotech stocks under $10. You can skip our detailed analysis of the biotech stocks and industry outlook, and go directly to see the 5 Best Biotech Stocks Under $10. Biotech stocks are facing a decline in September af...
Insider Monkey · 17h ago
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium
/PRNewswire/ --  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology De...
PR Newswire - PRF · 09/14 12:31
Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright 23r...
PR Newswire · 09/08 12:30
BRIEF-Anixa Biosciences Appoints Pamela Garzone As Chief Development Officer
reuters.com · 09/07 12:46
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.
Zacks · 08/31 15:08
Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer
Benzinga · 08/30 16:05
BRIEF-Anixa Biosciences Gets FDA Clearance For Ovarian Cancer Trial
reuters.com · 08/30 12:34
Anixa Biosciences And Moffitt Cancer Center Announce FDA Clearance To Initiate Clinical Trial Of Ovarian Cancer CAR-T Immunotherapy
 Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has
Benzinga · 08/30 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIX. Analyze the recent business situations of Anixa Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ANIX stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
High11.00
Average11.00
Low11.00
Current 4.800
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 38
Institutional Holdings: 2.98M
% Owned: 9.94%
Shares Outstanding: 29.95M
TypeInstitutionsShares
Increased
10
302.65K
New
8
248.10K
Decreased
4
23.91K
Sold Out
6
107.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Chairman/President/Chief Executive Officer/Director
Amit Kumar
Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Michael Catelani
Lead Director/Independent Director
Lewis Titterton
Independent Director
Arnold Baskies
Independent Director
Emily Gottschalk
No Data
  • All
  • Financials
  • Insiders
More
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on oncology and infectious disease. The Company is developing chimeric endocrine receptor T-cell technology, a chimeric antigen receptor T-cell (CAR-T) technology focused on treating ovarian cancer, and anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. It is also developing vaccine against triple negative breast cancer (TNBC), the lethal form of breast cancer, and a vaccine against ovarian cancer. Its subsidiary Certainty Therapeutics, Inc. (Certainty), is developing immuno-therapy drugs against cancer.

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.